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ABSTRACT
Objective An umbrella review summarising all safety data 
from systematic reviews of topical corticosteroids (TCS) in 
adults and children with atopic eczema.
Methods Embase, MEDLINE, PubMed, Cochrane Database 
of Systematic Reviews and the Centre of Evidence Based 
Dermatology map of eczema systematic reviews were 
searched until 7 November 2018 and Epistemonikos until 
2 March 2021. Reviews were included if they assessed the 
safety of TCS in atopic eczema and searched >1 database 
using a reproducible search strategy. Review quality was 
assessed using version 2 of 'A MeaSurement Tool to 
Assess systematic Reviews' (AMSTAR 2 tool).
Results 38 systematic reviews included, 34 low/critically 
low quality. Treatment and follow- up were usually short 
(2–4 weeks).
Key findings TCS versus emollient/vehicle: No meta- 
analyses identified for skin- thinning. Two 2- week 
randomised controlled trials (RCTs) found no significant 
increased risk with very potent TCS (0/196 TCS vs 0/33 
vehicle in children and 6/109 TCS vs 2/50 vehicle, age 
unknown). Biochemical adrenal suppression (cortisol) was 
3.8% (95% CI 2.4% to 5.8%) in a meta- analysis of 11 
uncontrolled observational studies (any potency TCS, 522 
children). Effects reversed when treatment ceased.
TCS versus topical calcineurin inhibitors: Meta- analysis 
showed higher relative risk of skin thinning with TCS (4.86, 
95% CI 1.06 to 22.28, n=4128, four RCTs, including one 
5- year RCT). Eight cases in 2068 participants, 7 using 
potent TCS. No evidence of growth suppression.
Once daily versus more frequent TCS: No meta- analyses 
identified. No skin- thinning in one RCT (3 weeks potent 
TCS, n=94) or biochemical adrenal suppression in two 
RCTs (up to 2 weeks very potent/moderate TCS, n=129).
TCS twice/week to prevent flares (‘weekend therapy’) 
versus vehicle: No meta- analyses identified. No evidence 
of skin thinning in five RCTs. One RCT found biochemical 
adrenal suppression (2/44 children, potent TCS).
Conclusions We found no evidence of harm when TCS were 
used intermittently ‘as required’ to treat flares or ‘weekend 
therapy’ to prevent flares. However, long- term safety data 
were limited.
PROSPERO registration number CRD42018079409.
INTRODUCTION
Atopic eczema (also known as atopic derma-
titis or eczema) is an itchy inflammatory skin 
condition. It is most common in children 
with one in five affected worldwide,1 2 but 
often persists into adulthood.3
Topical corticosteroids (TCSs) are first- line 
therapy for treating inflammatory eczema 
flares but widespread concerns regarding 
their safety among patients and healthcare 
professionals contribute to poor adherence, 
and subsequent worsening of disease control 
and quality of life.4 5 Safety concerns include 
skin thinning and retardation of growth and 
development. These concerns are thought to 
mainly originate from what is now considered 
to be inappropriate use, such as using potent 
TCS on the face or continual long- term use.6 
Strategies recommended to minimise expo-
sure to TCS, and hence the risk of adverse 
events, include reducing frequency of appli-
cation to once daily during treatment of an 
inflammatory episode, or TCS used for two 
consecutive days a week (sometimes referred 
to as ‘weekend therapy’) as a strategy to 
prevent flares.7–9 This umbrella review aims 
Strengths and limitations of this study
 ► Robust Cochrane methodology was followed and 
a thorough and inclusive literature search was 
performed to ensure this was a comprehensive 
overview.
 ► By extracting data from existing reviews, results are 
limited to topics for which there is an eligible sys-
tematic review.
 ► Safety was usually reported in less detail than effec-
tiveness in systematic reviews limiting the available 
data for extraction, therefore potentially missing 
data included in the original papers.
 ► Most included reviews were rated low or critically 
low- quality using AMSTAR 2, and where quality of 
evidence assessments were reported for individual 
studies most indicated a high or unclear risk in at 
least one domain.
 ► Many randomised controlled trials were only short 
in duration (2–4 weeks) limiting our ability to assess 
side effects that take longer to develop such as skin 
thinning.
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to assess safety (local and systemic adverse events) of TCS 
compared with other topical treatments, placebo or no 
comparator in people of any age and gender with atopic 
eczema, and addressed two areas of research prioritised 
in the James Lind Alliance priority setting partnership for 
atopic eczema.10
METHODS
Protocol, registration and study design
This umbrella review includes published systematic 
reviews of randomised controlled trials (RCTs) and/
or observational studies reporting adverse event data in 
people with eczema using TCS. The aim of this overview 
was to summarise data from existing reviews, therefore, 
meta- analyses and data from individual studies were 
extracted and presented in this overview in the format 
and completeness that they were presented in the original 
systematic reviews. The only exception was for missing 
p values which were calculated where appropriate. The 
checklist ‘Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA)’ was followed.11 12
Search strategy
Embase, MEDLINE, PubMed, Cochrane Database of 
Systematic Reviews and Epistemonikos were searched 
from inception to 7 November 2018 by DJCG (informa-
tion specialist), with no restrictions on language or publi-
cation date. The search strategy is in online supplemental 
appendix 1. The Epistemonikos search was updated on 2 
March 2021, with a publication date restricted to 2018–
2021. Epistemonikos is now well established as a compre-
hensive database of reviews that regularly searches ten 
major databases including the Cochrane Library, PubMed 
and Embase13 thus making the need to search these indi-
vidual databases redundant. We also checked the Centre 
of Evidence Based Dermatology eczema map of system-
atic reviews,14 and searched PROSPERO up to 23 March 
2021 for any relevant ongoing systematic reviews using 
the terms ‘eczema’ and ‘dermatitis’.
Eligibility criteria
We included systematic reviews that presented data on the 
safety of TCS used to treat people of any age and gender 
with atopic eczema, had clinical outcomes, searched at 
least one database and provided a reproducible search 
strategy. Systematic reviews of any types of clinical study 
design were included. Multiple reviews on the same topic 
were included, except for ‘abridged’ versions of the same 
review where no additional data were reported. To avoid 
duplication of data, for each comparison, the review that 
included the highest number of studies on that compar-
ison and therefore appeared the most comprehensive was 
taken as the primary review and other included reviews 
were checked for additional studies and data. Conference 
abstracts were excluded. Reviews that covered multiple 
skin conditions were only included if they reported data 
on atopic eczema patients separately.
Interventions and control
Our intervention of interest was any TCS of any prepa-
ration and potency used to treat atopic eczema. For 
RCTs, the comparisons of interest were any other TCS, 
the same TCS used in a different way, another topical 
anti- inflammatory treatment, vehicle, no treatment or 
a combination of any of these. Comparisons with non- 
topical treatments were excluded as we were interested in 
clinical practice decisions regarding alternatives to TCS.
Outcomes
Safety outcomes reported during the treatment and 
follow- up were extracted where reported in the reviews 
on immediate cutaneous adverse events (eg, burning 
sensation/stinging), other cutaneous adverse events (eg, 
skin thinning, telangiectasia, skin infections, folliculitis), 
systemic adverse events (eg, effects on endocrine system, 
impact on growth) and rebound symptoms/steroid 
withdrawal.
Selection of studies and data extraction
Records identified from the database searches were 
uploaded into Covidence (Veritas Health Innovation, 
Australia).15 Two authors (EA and JRC) independently 
assessed the eligibility of each record, and where unclear 
the full text was obtained. The number of included and 
excluded records along with reasons for exclusion were 
reported in a PRISMA flow diagram.
Two authors (EA and JRC) independently extracted all 
safety data presented in the included reviews along with 
other information such as review/participant character-
istics, and funding sources. Any disagreements regarding 
eligibility or data extraction were resolved via discussion 
or input from a third reviewer (HCW or KST). Where 
available, we reported results separately for age, filaggrin 
mutation status, TCS potency, site of application of the 
TCS, and duration of continuous treatment.
Assessment of quality of included systematic reviews
As this was an overview of reviews, the methodological 
quality of the evidence was assessed at the systematic 
review level using version 2 of 'A MeaSurement Tool to 
Assess systematic Reviews' (AMSTAR 2 tool) and this was 
conducted in duplicate by EA and JRC.16 Reviews were 
considered critically low quality if there was more than 
one critical flaw. Data on the quality of individual studies 
(eg, risk of bias) and the quality of evidence (eg, Grading 
of Recommendations Assessment, Development and Eval-
uation, GRADE17) were also extracted where presented 
in the review, but undertaking these quality assessments 
for individual studies was not within the remit of this 
overview.
Measures of treatment effect and data synthesis
Where relevant meta- analyses were presented in the 
systematic review, the forest plots, relative risk (RR) 
and 95% CI were extracted. In the absence of any meta- 
analysis, adverse event data from individual studies were 
included in this overview based on the data presented in 
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the published systematic review. P values were calculated 
using Review Manager software,18 with <0.05 indicating 
statistically significant results. Where meta- analyses were 
presented, we assessed the following subgroups where 
possible: age, TCS potency, anatomical site, treatment 
duration and genetic predisposition to a disrupted skin 
barrier (filaggrin status). TCS potency was determined 
using a hierarchy of sources: UK ‘British National Formu-
lary’, WHO and USA classifications.19–21 A National 
Health Service classification ranging from very common 
(>1 in 10 people affected) to very rare (<1 in 10 000) 
was used to narratively describe the absolute risk of each 
adverse event.22
Patient and public involvement
People with eczema and parents of children with eczema 
were involved in the decision to conduct this overview and 
in the design. The James Lind Alliance priority setting 
partnership for atopic eczema involved people with 
eczema and parents of children with eczema in which 
two of the identified priority areas were around research 
into the safety of TCS.10 Two of the overview authors are 
patient representatives (AR and AA) and both have been 
involved in the design of this overview and interpretation 
of the findings.
Wider patient and parent involvement has been partic-
ularly important in identifying important safety outcomes 
for this overview. We held a workshop involving five 
patient representatives in which the proposed overview 
was discussed which highlighted the need to seek out data 
on long- term TCS use, reversibility of any side effects and 
TCS withdrawal symptoms. We supplemented this with 
a survey about safety concerns with TCS at a National 
Eczema Society meeting of 31 people with eczema or 
parents of children with eczema and a published qualita-
tive study of patient concerns relating to TCS safety.6
Dissemination of the results is underway as part of the 
wider programme of research of which this overview is a 




After deduplication, 635 records were screened; 127 
records underwent full- text screening and 38 systematic 
reviews met the inclusion criteria (figure 1).7 8 23–56 The list 
of excluded reviews is in online supplemental appendix 2. 
The search of PROSPERO identified five ongoing system-
atic reviews (online supplemental appendix 3).57–61
Characteristics and quality of the included systematic reviews
All but three reviews were published in English. Two 
Chinese reviews and one German review were translated 
into English.32 36 45 Thirty of the included reviews were 
rated critically low quality according to AMSTAR 2; with 
four low, two moderate and two high quality (table 1). 
The most common reasons for downgrading were no 
protocol, no list of full- text exclusions or a literature 
search restricted to the English language.
The included reviews identified 106 studies (77 RCTs 
and 29 observational studies) that included relevant safety 
data. Risk of bias assessments were available from the 
reviews for 63 RCTs, of which 42 used the Cochrane risk 
of bias tool. Most of these assessments rated at least one 
domain as high or unclear risk, most noticeably selection 
bias from lack of allocation concealment, performance 
bias due to lack of blinding of participants and detec-
tion bias due to lack of blinding of outcome assessors. 
The trials included in the reviews usually evaluated use 
of short bursts of TCS (2–4 weeks) to treat the flare but 
varied greatly in length of follow- up. Around two- thirds 
of trials included no post- treatment follow- up, while the 
remainder included several weeks/months of follow- up 
generally using TCS intermittently ‘as required’. A total of 
14 RCTs (5874 participants) and 5 cohort/observational 
Figure 1 PRISMA flow diagram. PRISMA, Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses.
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Table 1 Characteristics of included systematic reviews
First author, 
publication year Type of review
Review contained safety data 
from RCTs for comparisons of 
interest?
Review contained 
safety data from 
observational studies? AMSTAR 2 rating
Ashcroft 200524 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6 7
Ashcroft 200723 Cochrane Yes (TCS vs TCI) Yes (TCS vs TCI) Moderate8
Barnes 201525 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
Yes (single arm TCS 
studies)
Critically low 1 2 3 4 6
Braham 201026 Non- Cochrane Yes (occluded TCS vs non- 
occluded TCS)
Yes (occluded TCS) Critically low 1 2 3 4 6
Broeders 201627 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 5 6
Callen 200728 Non- Cochrane Yes (TCS vs vehicle, TCS vs 
another TCS)
Yes (single arm studies 
or comparing TCS 
potencies)
Critically low 1 2 3 4 6
Chen 201029 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6
Cury Martins 201530 Cochrane Yes (TCS vs TCI) Yes (TCS vs TCI) Moderate8
De Tiedra 199731 Non- Cochrane Yes (TCS vs another TCS) Yes (usually only 
reported data from one 
arm of RCTs)
Critically low 1 2 3 4 6
Devillers 200632 Non- Cochrane Yes (occluded TCS vs non- 
occluded TCS)
Yes (occluded TCS) Critically low 1 2 3 4 6
Dong 201733 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 2 3 4 6
Eichenfield 201434 Non- Cochrane No Yes (different TCS 
potencies)
Critically low 1 2 3 4 6
Feldman 200535 Non- Cochrane Yes (TCS vs vehicle) No Critically low 1 2 3 4 6
Fishbein 201963 Non- Cochrane Yes (TCS vs vehicle/moisturiser) No Critically low 3 4 5 6 7
Frangos 200836 Non- Cochrane Yes (TCS vs vehicle) Yes (single arm studies) Critically low 1 2 3 4 6
Froeschl 200737 GMS HTA report Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
No Critically low 1 2 4 6
Gonzalez- Lopez 
201738
Non- Cochrane Yes (occluded TCS vs non- 
occluded TCS)
No Critically low 1 3
Green 20047 HTA report Yes (once daily vs twice daily TCS 
use)
No Low
Gu 201340 Cochrane Yes (TCS vs topical CHM) No High
Gu 201439 Non- Cochrane Yes (TCS vs topical CHM) No Critically low 1 2 3 7
Hajar 201541 Non- Cochrane No Yes (case series or case 
reports)
Critically low 2 3 6
Hoare 200042 NIHR HTA report Yes (TCS vs vehicle, TCS vs 
another TCS)
No Low
Iskedjian 200443 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI) No Critically low 1 3 6
Juhász 201744 Non- Cochrane No Yes (social media 
analysis)
Critically low 1 2 3 4 6
Abędź 201982 Non- Cochrane Yes (TCS vs TCI) No Critically low1 3 6 7
Legendre 201545 Non- Cochrane No Yes (TCS vs TCI) Critically low 1 2 3 6
Li 200746 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6
Nankervis 201647 NIHR HTA report Yes (TCS vs vehicle, TCS vs 
emollients, TCS vs TCI, TCS 
vs another TCS, once a day vs 
twice a day use, proactive TCS to 
prevent flares (‘weekend therapy’) 
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studies (4 438 698 participants) out of a total of 106 
studies included follow- up of more than 3 months. One 
notable trial (the ‘PETITE’ study) had 5 years follow- up 
with TCS used ‘as required’.62
Characteristics and quality assessments of each system-
atic review are in table 1, with further detail in online 
supplemental appendices 4 and 5. Individual study data 
and quality assessments are in online supplemental 
appendix 6.
Safety of TCS compared with other topical treatments or 
corticosteroids
How safe are TCS compared with emollient or vehicle, or no 
comparison?
Thirteen reviews provided data on this comparison: 1 
high54, 2 low42 47 and 10 critically low quality.25 28 31 35–37 50 51 55 63 
Key results can be found in table 2 and additional data in 
online supplemental appendix 6.
Reported rates of skin thinning in RCTs were gener-
ally very low, with no significant increases seen with TCS 
compared with emollient/vehicle. No skin thinning or 
telangiectasia was reported in an RCT, 196 participants 
aged ≥12 years old using very potent TCS twice a day 
for 2 weeks compared with 33 using vehicle.64 Another 
RCT reported skin thinning in 6/109 participants using 
very potent TCS for 2 weeks compared with 2/50 using 
vehicle, p=0.69.65
No significant differences in other cutaneous adverse 
events, such as hypopigmentation, were observed between 
treatments in five RCTs, and event rates were low.66–70
A meta- analysis55 of 11 uncontrolled observational 
studies (up to 4 weeks of treatment) reported biochem-
ical adrenal suppression (cortisol levels) in 20/522 chil-
dren (3.8%, 95% CI 2.4% to 5.8%) with any potency 
TCS.71–81 This was 2% (3/148 children) when only mild 
potency TCS were analysed.72 74 77 79 No clinical symptoms 
or signs of adrenal suppression were observed,71–81 and 
the biochemical effects were transient, with cortisol levels 
returning to normal after TCS were discontinued.71 75 77 78 81
Two included reviews assessed TCS withdrawal symp-
toms, mostly from case reports, but no incidence data 
were reported.41 44
How safe are TCS compared with topical calcineurin inhibitors?
Eight systematic reviews were identified: one moderate23, 
one low48 and six critically low quality.27 30 43 50 52 82 Most 
RCTs used twice daily TCS to treat the current flare (up to 
3 weeks), and where longer- term follow- up was included, 
TCSs were used ‘as required’ to treat flares. Key results 
First author, 
publication year Type of review
Review contained safety data 
from RCTs for comparisons of 
interest?
Review contained 
safety data from 
observational studies? AMSTAR 2 rating
Burls 200448 West Midlands HTA 
report
Yes (TCS vs TCI) No Low
Schmitt 20118 Non- Cochrane Yes (proactive TCS to prevent 
flares (‘weekend therapy’) vs 
vehicle)
No Critically low 3 6
Sidbury 201449 Non- Cochrane Yes (proactive TCS to prevent 
flares (’weekend therapy’) vs 
vehicle)
No Critically low 1 2 3 4 6
Siegfried 201650 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
No Critically low 1 2 3 4 6
Singh 201251 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
Yes (single arm study) Critically low 1 2 6
Svensson 201152 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6 7
Tang 201453 Non- Cochrane Yes (proactive TCS to prevent 
flares (‘weekend therapy’) vs 
vehicle)
No Critically low 1 3 4 6
van Zuuren 201754 Cochrane Yes (TCS vs emollient) No High
Wood Heickman 
201855
Non- Cochrane No Yes (single arm cohort 
studies)
Critically low 1 2 3 4 6 7
Yan 200856 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6 7
AMSTAR 2 ratings—reasons for downgrading the quality of the review: 1No protocol; 2Search strategy not comprehensive; 3No list of 
excluded studies with reasons; 4Risk of bias not assessed; 5Inappropriate meta- analysis methods; 6Risk of bias assessments not included in 
the interpretation of the results; 7Publication bias not explored in the meta- analysis.
Additional data on TCS including potency can be found in online supplemental appendix 6.
CHM, Chinese herbal medicine; GMS, German Medical Science; HTA, Health Technology Assessment; NIHR, National Institute for Health 
Research; RCTs, randomised controlled trials; TCI, topical calcineurin inhibitors; TCS, topical corticosteroid.
Table 1 Continued
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Table 2 Summary of main findings for key safety outcomes
Cutaneous adverse events Systemic adverse events
How safe are TCS compared 





10 critically low quality
 ► Skin thinning: No significant differences in 2 
RCTs of 2–4 weeks compared with emollient/
vehicle: (1) 0/196 children with very potent 
TCS and 0/33 vehicle, (2) 6/109 very potent 
TCS vs 2/50 vehicle, p=0.69. Very low rates.
 ► Other cutaneous adverse events: No 
significant differences in 5 RCTs (2–4 weeks) 
between TCS (various potencies) and 
emollient/vehicle (n=172, plus one study, n 
not specified). Low event rates.
 ► Biochemical evidence of adrenal 
suppression: Meta- analysis (11 
observational studies, max 4 
weeks)—20/522 children with any 
potency TCS (3.8%, 95% CI 2.4% to 
5.8%), 3/148 children (2%) with mild 
potency TCS. Effects were transient.
 ► Clinical symptoms or signs of 
adrenal suppression: none observed 
in same as above observational 
studies.
How safe are TCS compared 





6 critically low quality
 ► Skin thinning: Higher with TCS than TCI 
(meta- analysis of 4 RCTs: RR 4.86, 95% 1.06 
to 22.28, n=4128) but very low rate (8/2068, 
7 of which were using potent TCS).
 ► Other cutaneous adverse events: No 
difference in skin infections between TCS 
and TCI (8 RCTs). Skin burning and pruritus 
lower with TCS than TCI: meta- analysis of 
10 RCTs: burning—RR 0.31, 95% CI 0.23 to 
0.40 (n=4211), pruritus—RR 0.68, 95% CI 
0.56 to 0.82(n=4211).
 ► Growth rate: no differences in growth 
rates tween TCS and TCI (1 RCT of 
2418 children with 5 years follow- up).
 ► Lymphoma: no cases reported in one 
same large RCT as above. One cohort 
study (n=1 438 333, approx. 4 years 
follow- up)—very small non- significant 
increase with TCI and TCS compared 
with general population. One case–
control study—no increased risk with 
TCS or TCIs (294 cases/293 000 
controls).
How safe are once daily TCS 




 ► Skin thinning: no cases using once daily vs 
twice daily potent TCS for 3 weeks (1 RCT, 
94 adults).
 ► Other cutaneous adverse events: no 
significant difference between groups in 
telangiectasia, folliculitis, or burning/
itching/stinging (4 RCTs, 4–16 weeks 
follow- up 740 older children/adults).
 ► Biochemical evidence of adrenal 
suppression: no significant differences 
between once and twice daily 
moderate/potent TCS up to 2 weeks in 
children (2 RCTs, n=129).
How safe are TCS used 
proactively to prevent flares 
(‘weekend therapy’)?
3 reviews:
3 critically low quality
 ► Skin thinning: no cases with 16–20 weeks 
of 2 days/week of potent TCS vs vehicle (5 
RCTs, n=993).
 ► Other cutaneous adverse events: no 
significant differences between groups, 
including folliculitis and transient 
telangiectasia, with potent TCS (16–20 
weeks) compared with either vehicle or 
another TCS (2 RCTs, n=423). Events were 
uncommon in both groups.
 ► Biochemical evidence of adrenal 
suppression: no cases with 16 weeks 
of 2 days/week of potent TCS (2 RCTs, 
n=129). Possible adrenal suppression 
in 2/44 children with potent TCS 
compared with zero using vehicle (1 
RCT, 20 weeks).




3 critically low quality
 ► Skin thinning: no cases in two observational 
studies (potent TCS +wet wrap, 1–2 weeks, 
n=44).
 ► Other cutaneous adverse events: One 
case of striae in two observational studies, 
n-44. More folliculitis with diluted potent 
TCS (10/19 children) compared with 
emollient (2/20), both under wet wrap (1 
RCT). A meta- analysis (2 RCTs, n=69) of wet 
wrap vs no wet wrap (mild potency)—no 
significant difference in cutaneous adverse 
events.
 ► Biochemical evidence of adrenal 
suppression: reported in three 
observational studies (2–14 days of 
diluted potent TCS under wet- wraps in 
74 children) but rates not specified in 
review. Described as transient in two 
studies.
 ► Growth or bone turnover: no 
effect seen in one small short- term 
observational study (potent TCS wet- 
wrap in eight children, (median follow- 
up 12 weeks).
RCTs, randomised controlled trials; RR, relative risk; TCS, topical corticosteroids.
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can be found in table 2 and additional data in online 
supplemental appendix 6.
Meta- analyses of cutaneous adverse events were 
presented in two reviews.27 82 So the more comprehen-
sive review was used to extract the cutaneous adverse 
event data.27 Some minor modifications were made to 
the data for this overview shown in online supplemental 
appendix 7. A meta- analysis of four RCTs (26 weeks to 
5 years duration, twice a day or ‘as directed’) showed a 
significant increase in the RR of skin thinning with TCS 
compared with topical calcineurin inhibitors (TCIs) 
(0.1% tacrolimus or 1% pimecrolimus) (RR 4.86, 95% CI 
1.06 to 22.28, p=0.04, n=4128). However, skin thinning 
was uncommon: 8/2068 participants (0.4%) with TCS vs 
0/2060 (0%) with TCIs. Of the eight cases of skin thin-
ning, seven were reported when using potent TCS and 
one using mild/moderate TCS.62 83–85
The RR of skin burning and pruritus (itching) was 
significantly lower with TCS compared with TCIs (1% 
pimecrolimus or 0.1 % / 0.03% tacrolimus) in meta- 
analyses of 10 RCTs in 4211 participants (skin burning: RR 
0.31, 95% CI 0.23 to 0.40, p<0.00001; pruritus: RR 0.68, 
95% CI 0.56 to 0.82, p<0.0001).83 85–93 The GRADE assess-
ments for these two adverse events indicated these were 
of moderate quality.82 There was no significant difference 
in skin infections with potent, moderate or mild potency 
TCS compared with TCIs (1% pimecrolimus or 0.1 
%/0.03% tacrolimus)62 83–86 88 90 92 or erythema compared 
with 0.1% tacrolimus (online supplemental appendix 
8).91 92
Subgroup analyses of age, TCS potency and specific 
TCI showed no significant differences for any compar-
ison (online supplemental appendix 9). We were unable 
to undertake any further subgroup analyses.
No differences in growth were observed in one 5- year 
RCT (‘PETITE’ study) in 2418 young children using 
moderate/mild potency TCS compared with those using 
TCI (1% pimecrolimus) (rates not given) and no cases 
of lymphoma were reported.62 A large cohort study (n=1 
438 333) showed a small non- significant increased risk of 
lymphoma with TCI and TCS compared with the general 
population, with a similar risk between treatments.94 In 
addition, one case–control study (294 cases/293 000 
controls) found no increased risk of lymphoma with TCS 
or TCI compared with controls.95
Is there any difference in safety of TCS of different potencies?
Six reviews compared the safety of different potency TCS: 
two low,42 47 and four critically low quality.28 34 50 53 RCTs 
were mainly short- term use of TCS (2–3 weeks), used 
once or twice daily. Results can be found in online supple-
mental appendix 6.
One RCT reported mild skin thinning in 4/13 chil-
dren using potent TCS for up to 6 weeks compared 
with 2/12 using mild TCS (p=0.42),96 while another 
RCT in 37 children found no evidence of skin thinning 
with mild or moderate potency TCS for 3 weeks.97 One 
study compared 3 weeks of potent and moderate TCS in 
40 children and reported ‘some’ biochemical adrenal 
suppression (cortisol levels) but no numerical data were 
provided.98
How safe are TCS compared with topically applied Chinese herbal 
medicine?
Two systematic reviews provided data on TCS compared 
with topical Chinese herbal medicine: one high quality40 
and one critically low.39 Results can be found in online 
supplemental appendix 6.
A meta- analysis of two RCTs99 100 was presented in two 
systematic reviews.39 40 More cutaneous adverse events, 
including application site burning, were observed with 2 
weeks of very potent/potent TCS compared with topical 
Chinese herbal medicine (RR 12.03, 95% CI 1.59 to 
91.26, p=0.02; 11/147 vs 0/148 participants). One addi-
tional RCT, including 95 young children, reported minor 
adverse events such as burning with 2 weeks of potent 
TCS but no numerical data were presented.101
Safety of different strategies for using TCS
How safe are once daily TCS compared with more frequent 
application?
Two low- quality reviews provided safety data relating to 
different frequency of application.7 47 Key results can be 
found in table 2 and additional data in online supple-
mental appendix 6.
No skin thinning was reported with once or twice 
daily application of potent TCS for 3 weeks in one RCT 
(94 adults).102 Four RCTs in 740 older children/adults 
showed no significant difference between once and twice 
daily application of moderate/potent TCS in other cuta-
neous adverse events including telangiectasia,103 104 follic-
ulitis105 and burning, itching or stinging.105 106 Two RCTs 
showed no significant differences in biochemical adrenal 
suppression (cortisol levels) between once and twice daily 
very potent/moderate TCS used for up to 2 weeks in 129 
children.81 107
How safe are TCS when used proactively to prevent flares 
(‘weekend therapy’)?
Two reviews included data on the safety of TCS used 
proactively 2 days a week (‘weekend therapy’) to prevent 
flares, both critically low quality.8 53 Key results can be 
found in table 2 and additional data in online supple-
mental appendix 6.
There was no evidence of skin thinning in five RCTs 
comparing 16–20 weeks of weekend therapy with potent 
TCS versus vehicle in 993 participants.103 108–111 Further-
more, two RCTs (n=423) reported no significant differ-
ences in other cutaneous adverse events, including 
folliculitis and transient telangiectasia, with potent TCS 
compared with vehicle.108 109 Events were uncommon in 
both groups.
There was no evidence of biochemical adrenal suppres-
sion (cortisol levels) in two RCTs (n=129) between potent 
TCS and vehicle used for 16 weeks.108 111 In a 20- week 
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RCT, 2/44 children had possible adrenal suppression 
with potent TCS compared with zero with vehicle.109
How safe are TCS used under occlusion?
Four reviews included data on the safety of TCS used 
under occlusion: one high54, and three critically low 
quality.26 32 38 Results can be found in online supplemental 
appendix 6.
There were no cases of skin thinning and one case 
of striae in two uncontrolled observational studies of a 
diluted potent TCS used under wet- wrap for 1–2 weeks 
in 44 young children.112 113 A significant difference in the 
rate of folliculitis (mostly mild) was observed in one RCT 
of TCS under wet- wrap for 4 weeks, with more follicu-
litis in the diluted potent TCS group (10/19 children) 
compared with emollient (2/20 children) (p=0.02).114 A 
meta- analysis from one review38 of two RCTs in young chil-
dren showed no significant difference in the number of 
participants with cutaneous adverse events between mild 
potency TCS under wet wrap (7/38 participants) versus 
not under wet- wrap (0/31 participants) (p=0.08)115 116; 
this evidence was rated low quality by the systematic review 
authors using GRADE.17
Biochemical adrenal suppression (cortisol levels) was 
reported in three uncontrolled observational studies of 
2–14 days of diluted potent TCS under wet- wraps in 74 
children.112 113 117 Actual rates were not specified in the 
review, but increases were described as transient in two 
studies.112 117 One short- term uncontrolled observational 
study of diluted potent TCS under wet- wrap in eight chil-
dren showed no effect on growth or bone turnover.118
DISCUSSION
This comprehensive overview of systematic reviews 
which, for the first time, brings together all safety data 
from systematic reviews on TCS used in eczema from 38 
systematic reviews, a topic that was identified as a priority 
in a James Lind Alliance priority setting partnership on 
eczema. Skin thinning and effects on growth concern 
many people with eczema and parents of children with 
eczema when using TCS. However, we found no evidence 
of skin thinning when TCS were used intermittently ‘as 
required’ to treat flares or as ‘weekend therapy’ to prevent 
flares, although the majority of data was from short- 
term studies.5 Similarly, we found no evidence of growth 
retardation or clinically significant adrenal suppression 
but the only data available was from one 5- year study 
that included 1213 children using TCS.62 Other studies 
only reported biochemical signs of adrenal suppression. 
Adherence to TCS treatment is known to be poor and 
these findings, particularly around skin thinning, may 
encourage appropriate use of TCS and therefore improve 
treatment effectiveness and patient benefit.119
A thorough literature search was conducted and 
Cochrane methodology was used. Conclusions were 
limited by the content of the included reviews because 
safety was frequently reported in less detail than 
effectiveness, reviews reported on different adverse 
events and some adverse events were not described in 
the reviews. It is not clear whether this is because the 
trials did not report adverse events in sufficient detail or 
whether the review authors did not include all the avail-
able safety data, perhaps only focusing on a restricted 
group of adverse events. None of the included systematic 
reviews presented data on our prespecified subgroup 
analyses. Furthermore, most of the included reviews were 
rated low or critically low- quality using AMSTAR 2. The 
lack of comprehensive search strategies and duplicate 
screening/data extraction in the included reviews may 
have resulted in missing studies and safety data, which 
could have impacted on this overview particularly where 
there was limited data. In addition, where the quality of 
evidence assessments (eg, GRADE) were reported in the 
reviews, most individual studies included in the reviews 
indicated a high or unclear risk in at least one domain.
Many RCTs did not include follow- up beyond 2–4 weeks 
of treatment and therefore data on long- term safety are 
limited. Although short- term TCS use reflects appropriate 
treatment duration for treating an individual flare, it does 
not reflect the chronic nature of eczema and the need 
for TCS use over the long- term. The ‘PETITE study’ was 
the notable exception and data published in the corre-
spondence showed there was only one episode of skin 
thinning in 1213 children using mild/moderate TCS ‘as 
required’ with 5- year follow- up.62 Trials using intermittent 
TCS as ‘weekend therapy’ to prevent flares also provide 
reassurance for the safety of longer- term use of TCS, as 
these trials generally included 16–20 weeks of follow- up 
to assess the prevention of flares. The inclusion of system-
atic reviews that included observational studies as well as 
reviews of RCTs also increased the amount of safety data 
available to report in this overview.
Although this review focused on the safety of TCS as the 
key issue for patients, treatment decisions are a balance 
of benefits and harms. For example, although the safety 
profile of Chinese herbal medicine was better than TCS, 
in practice this would be considered alongside the rela-
tive effectiveness of these treatments. Likewise, although 
there was no difference in the safety of once vs twice daily 
TCS, effectiveness of these regimens is also important to 
consider. A Cochrane review is underway comparing the 
effectiveness and safety of different ways of using TCS.120
In summary, we found no evidence that TCS cause 
harm when used intermittently ‘as required’ to treatment 
eczema flares or as ‘weekend therapy’ to prevent flares 
and this should support the use of TCS in the manage-
ment of eczema. We found that the adverse events of 
greatest concern to patients and clinicians, such as skin 
thinning, are uncommon with short- term use of TCS. 
However, high- quality evidence was limited, particularly 
for long- term use. Rather than follow- up of perhaps just a 
few weeks, future RCTs should include lengthier follow- up 
to enable better safety assessment. However, it should be 
noted that longer- term prospect observational studies are 
better placed to explore longer- term safety of TCS and 
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should be designed with years rather than months of 
follow- up to add useful information to the field. Perhaps 
equally as important as duration of follow- up in trials is 
resolution of adverse events which is often not reported. 
For adverse events such as biochemical signs of adrenal 
suppression, it is crucial to know if the effect is transient 
and levels return to normal once the TCS is stopped, 
particularly as it is not clear how to interpret the clinical 
relevance of these.
Twitter Matthew J Ridd @riddmj and Ingrid Muller @IngridMuller7
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Uses PubMed Clinical Queries systematic review filter (command systematic[sb]):
https://www.nlm.nih.gov/bsd/pubmed_subsets/sysreviews_strategy.html
(steroid* OR corticosteroid* OR glucocorticosteroid* OR glucocorticoid* OR glucocorticoids[MeSH Terms] OR
alclometasone OR alclomethasone OR amcinonide OR beclometasone OR beclomethasone OR
beclomethasone[MeSH Terms] OR betametasone OR betamethasone OR betamethasone[MeSH Terms] OR
clobetasol OR clobetasol[MeSH Terms] OwR clobetasone OR desonide OR desonide[MeSH Terms] OR
desoximetasone OR desoximetasone[MeSH Terms] OR diflorasone OR diflucortolone OR diflucortolone[MeSH
Terms] OR fludroxycortide OR flumetasone OR flumethasone OR flumethasone[MeSH Terms] OR fluocinolone
OR fluocinolone acetonide[MeSH Terms] OR fluocinonide OR fluocinonide[MeSH Terms] OR fluocortolone OR
fluocortolone[MeSH Terms] OR flurandrenolide OR flurandrenolone OR flurandrenolone[MeSH Terms] OR
fluticasone OR halcinonide OR halcinonide[MeSH Terms] OR halobetasol OR halometasone OR hydrocortisone
OR hydrocortisone[MeSH Terms] OR methylprednisolone OR methylprednisolone[MeSH Terms] OR
mometasone OR triamcinolone OR triamcinolone[MeSH Terms]) AND ("dermatitis, atopic"[MeSH Terms] OR
"eczema"[MeSH Terms] OR "neurodermatitis"[MeSH Terms] OR eczema OR "atopic dermatitis" OR
neurodermatitis) AND (systematic[sb] OR "systematic review")
Ovid MEDLINE search
Uses SIGN MEDLINE systematic review filter:
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OR clobetasone OR desonide OR desoximetasone OR diflorasone OR diflucortolone OR fludroxycortide OR
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methylprednisolone OR mometasone OR triamcinolone) AND (eczema OR "atopic dermatitis" OR
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(steroid* OR corticosteroid* OR glucocorticosteroid* OR glucocorticoid* OR [mh "glucocorticoids"] OR
alclometasone OR alclomethasone OR amcinonide OR beclometasone OR beclomethasone OR betametasone
OR betamethasone OR clobetasol OR clobetasone OR desonide OR desoximetasone OR diflorasone OR
diflucortolone OR fludroxycortide OR flumetasone OR flumethasone OR fluocinolone OR fluocinonide OR
fluocortolone OR flurandrenolide OR flurandrenolone OR fluticasone OR halcinonide OR halobetasol OR
halometasone OR hydrocortisone OR methylprednisolone OR mometasone OR triamcinolone) AND ([mh
"eczema"] OR [mh "dermatitis, atopic"] OR [mh "neurodermatitis"] OR eczema OR "atopic dermatitis" OR
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Appendix 2 - list of excluded studies with reasons
Excluded study Reason for exclusion
Abramovits 2005 (1) Not a systematic review
Abramovits 2006 (2) Not a systematic review
Anonymous 1995 (3) Not a systematic review
Anonymous 1999 (4) Not a systematic review
Anonymous 2004 (5) Not a systematic review
Anonymous 2005 (6) Abstract
Anonymous 2007 (7) Not a systematic review
Anonymous 2015 (8) Abstract
Anonymous 2015 (9) Abstract
Aslam 2014 (10) Not a systematic review
Barfield 2017 (11) Wrong intervention (not topical corticosteroids)
Batchelor 2010 (12) Not a systematic review
Bath-Hextall 2010 (13) Updated version of a Cochrane review (non-Cochrane) but no additional safety data
Bigby 2001 (14) Commentary paper
Bonchak 2017 (15) Wrong intervention (not topical corticosteroids)
Birnie 2008 (16) Wrong intervention (not topical corticosteroids)
Boucher 2001 (17) Not a systematic review
Broersen 2015 (18) Unable to extract separate data for atopic eczema patients
Cameron 2000 (19) Commentary paper
Carbone 2010 (20) Not a systematic review
Chavigny 2005 (21) Not a systematic review
Chi 2009 (22) Unable to extract separate data for atopic eczema patients
Chi 2015 (23) Unable to extract separate data for atopic eczema patients
Chia 2015 (24) Not a systematic review
Chu 1995 (25) Not a systematic review
Conroy 2004 (26) Not a systematic review
Das 2017 (27) Not a systematic review
El-Batawy 2009 (28) No safety outcome
Fleischer Jr 2010 (29) Wrong intervention (not topical corticosteroids)
Frohna 2005 (30) Commentary paper
Froschl 2007 (31) Duplicate record of an included systematic review
Furue 2006 (32) Not a systematic review
Furue 2006 (33) Not a systematic review
Garside 2005 (34) No safety outcome
Ghajar 2019 (35) ‘Subgroup analysis’ of an included review (Wood Heickman 2018) – no additional safety data
Goustas 2003 (36) Not a systematic review
Green 2005 (37) Duplicate record of an included systematic review
Green 2004 (38) Duplicate record of an included systematic review
Halling-Overgaard 2017 (39) Skin atrophy is not assessed clinically in this review
Health Technology Assessment
Database 2004 (40)
Not a systematic review
Health Technology Assessment
Database 2004 (41)
Abstract – unable to find the full publication
Health Technology Assessment
Database 2001 (42)
Abstract – unable to find the full publication
Health Technology Assessment
Database 2004 (43)
Abstract – unable to find the full publication
Hannuksela 2000 (44) Wrong intervention (not topical corticosteroids)
Hebert 2006 (45) Wrong intervention (not topical corticosteroids)
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Hoare 2000 (46) Duplicate record of an included systematic review
Hon 2011 (47) Wrong intervention (not topical corticosteroids)
Hulshof 2017 (48) Wrong intervention (not topical corticosteroids)
Hussain 2016 (49) Not a systematic review
Kaufman 2016 (50) Abstract
Legendre 2015 (51) Abstract
Li 2017 (52) Abstract
Li 2017 (53) No safety outcome
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1 Did the research questions and inclusion criteria for the review include the components of PICO?
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*7 Did the review authors provide a list of excluded studies and justify the exclusions?
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NB domains marked * in the table and footnotes are critical domains.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
1. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or
non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
2. Ashcroft D, Dimmock P, Garside R, Stein K, Williams H. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic
dermatitis: Meta-analysis of randomised controlled trials. BMJ 2005;330(7490):516-22.
3. Ashcroft DM, Chen L-C, Garside R, Stein K, Williams HC. Topical pimecrolimus for eczema Cochrane Database Syst Rev [Internet]. 2007; (4). Available
from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005500.pub2/abstract.
4. Barnes L, Kaya G, Rollason V. Topical Corticosteroid-Induced Skin Atrophy: A Comprehensive Review. Drug Saf. 2015;38(5):493-509.
5. Braham S, Pugashetti R, Koo J, Maibach H. Occlusive therapy in atopic dermatitis: overview. J Dermatolog Treat. 2010;21(2):62-72.
6. Broeders J, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors
with topical corticosteroids for atopic dermatitis: A 15-year experience. J Am Acad Dermatol. 2016;75(2):410-9.e3.
7. Callen J, Chamlin S, Eichenfield L, Ellis C, Girardi M, Goldfarb M, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J
Dermatol. 2007;156(2):203-21.
8. Chen S, Yan J, Wang F. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: A meta-analysis of randomized
clinical trials. J Dermatolog Treat. 2010;21(3):144-56.
9. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da SEM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev [Internet]. 2015;
(7). Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009864.pub2/abstract.
10. de Tiedra A, Mercadal J, Lozano R. Prednicarbate versus fluocortin for inflammatory dermatoses: A cost-effectiveness study. PharmacoEconomics.
1997;12(2 Pt 1):193-208.
11. Devillers A, Oranje A. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic
dermatitis: a critical review of the literature. Br J Dermatol. 2006;154(4):579-85.
12. Dong Y, Zeng W, Li W, Ma H, Zheng W. Efficacy and safety of topical tacrolimus for childhood atopic dermatitis; a meta-analysis. [Chinese]. J Clin
Dermatol. 2017;46(4):239-42.
13. Eichenfield L, Tom W, Berger T, Krol A, Paller A, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: Section 2.
Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32.
14. Feldman S. Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses.
Curr Ther Res Clin Exp. 2005;66(3):154-71.
15. Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic Review and Meta-analysis Comparing Topical Corticosteroids With
Vehicle/Moisturizer in Childhood Atopic Dermatitis. J Pediatr Nurs. 2019;47:36-43.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
16. Frangos J, Kimball A. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opin
Pharmacother. 2008;9(11):2001-7.
17. Froeschl B, Arts D, Leopold C. Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis (Structured abstract). Health
Technol Assess [Internet]. 2007; (4). Available from: http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32008100208/frame.html.
18. Gonzalez-Lopez G, Ceballos-Rodriguez R, Gonzalez-Lopez J, Feito Rodriguez M, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients
with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(3):688-95.
19. Green C, Colquitt J, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical
corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2004;8(47):iii,iv, 1-120.
20. Gu S, Yang AW, Xue CC, Li CG, Pang C, Zhang W, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev [Internet]. 2013; (9).
Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008642.pub2/abstract.
21. Gu S, Yang A, Li C, Lu C, Xue C. Topical application of Chinese herbal medicine for atopic eczema: A systematic review with a meta-analysis.
Dermatology. 2014;228(4):294-302.
22. Hajar T, Leshem Y, Hanifin J, Nedorost S, Lio P, Paller A, et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in
patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-9.e2.
23. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1-191.
24. Iskedjian M, Piwko C, Shear N, Langley R, Einarson T. Topical calcineurin inhibitors in the treatment of atopic dermatitis: A meta-analysis of current
evidence. Am J Clin Dermatol. 2004;5(4):267-79.
25. Juhász ML, Curley RA, Rasmussen A, Malakouti M, Silverberg N, Jacob SE. Systematic Review of the Topical Steroid Addiction and Topical Steroid
Withdrawal Phenomenon in Children Diagnosed With Atopic Dermatitis and Treated With Topical Corticosteroids. J Dermatol Nurses Assoc. 2017;9(5):233-
40.
26. Łabędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized 
clinical trials. Postepy Dermatol Alergol. 2019;36(6):752-9.
27. Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of
topical treatment: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992-1002.
28. Li R, Zhu H, Fan L, Ni S, Feng C, Wu Z. Efficacy and tolerability of topical tacrolimus in the treatment of atopic dermatitis: A systematic review of
randomized controlled trials. [Chinese]. J Clin Dermatol. 2007;36(12):757-60.
29. Nankervis H, Thomas K, Delamere F, Barbarot S, Rogers N, Williams H. Scoping systematic review of treatments for eczema2016 2016/05/None.
30. Penaloza Hidalgo B, Knight T, Burls A. A systematic review of effectiveness and cost effectiveness of tacrolimus ointment for topical treatment of
atopic dermatitis in adults and children Health Technol Assess [Internet]. 2004; (4):[81 p.].
31. Schmitt J, Von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin
inhibitors for atopic eczema: Systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415-28.
32. Sidbury R, Tom W, Bergman J, Cooper K, Silverman R, Berger T, et al. Guidelines of care for the management of atopic dermatitis: Section 4.
Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218-33.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
33. Siegfried E, Jaworski J, Kaiser J, Hebert A. Systematic review of published trials: Long-term safety of topical corticosteroids and topical calcineurin
inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16 (75).
34. Singh S, Mann B. Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: A systematic review. Clin
Cosmet Investig Dermatol. 2012;5:61-8.
35. Svensson A, Chambers C, Gånemo A, Mitchell S. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of
atopic dermatitis. Curr Med Res Opin. 2011;27(7):1395-406.
36. Tang T, Bieber T, Williams H. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically
useful? J Allergy Clin Immunol. 2014;133(6):1615-25.e1.
37. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen AP, Arents BW. Emollients and moisturisers for eczema. Cochrane Database Syst Rev
[Internet]. 2017; (2). Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012119.pub2/abstract.
38. Wood Heickman L, Davallow Ghajar L, Conaway M, Rogol A. Evaluation of Hypothalamic-Pituitary-Adrenal Axis Suppression following Cutaneous
Use of Topical Corticosteroids in Children: A Meta-Analysis. Horm Res Paediatr. 2018;89(6):389-96.
39. Yan J, Chen S, Wang X, Zhou W, Wang F. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol.
2008;25(1):117-20.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E












Non-Cochrane English NHS health technology assessment
programme.
None known TCS versus TCI No Critically low
Ashcroft 2007
(2)
Cochrane English School of Pharmacy and
Pharmaceutical Sciences, University
of Manchester, UK.
None known TCS versus TCI Yes – TCI compared with TCS Moderate
Barnes 2015
(3)
Non-Cochrane English No funding None known TCS versus vehicle
TCS versus TCI
TCS versus TCS
Yes (single arm TCS studies) Critically low
Braham 2010
(4)










Non-Cochrane English No funding None known TCS versus TCI No Critically low
Callen 2007 (6) Non-Cochrane English Funding from EBMed. One author
received funding from Novartis
Corporation for the project. They
declared that “Novartis Corporation
played no role in the design and
conduct of the study or in data
collection, data management, data
analysis, interpretation of the data,
manuscript preparation, manuscript
review or manuscript approval”
Most authors had consultancy fees








Chen 2010 (7) Non-Cochrane English Not stated None known TCS versus TCI No Critically low
Cury Martins
2015 (8)
Cochrane English NIHR None known TCS versus TCI Yes – TCI compared to TCS Moderate
De Tiedra
1997 (9)
Non-Cochrane English Supported by Laboratorios Novag,
S.A, Grupo Ferrer.
Not clear TCS versus TCS Yes – in most cases they only





Non-Cochrane English Not stated None known Occlusive therapy versus
non-occlusive therapy
Yes – occlusive therapy (no
comparison)
Critically low
Dong 2017 (11) Non-Cochrane Chinese Not stated Not clear TCS versus TCI No Critically low
Eichenfield
2014 (12)
Non-Cochrane English No funding Most authors served as consultants,
speakers, members of the advisory
None Yes (comparing different TCS
potencies)
Critically low
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E




Non-Cochrane English Grant from Galderma Laboratories,
LP, Fort Worth, Texas.
Not clear TCS versus vehicle No Critically low
Fishbein 2019
(14)





Non-Cochrane English Not stated One author is an investigator for
Steifel and was an investigator on
two of the studies reviewed.





















HTA report English Funded by the HTA Programme on
behalf of NICE
None known Once daily versus twice
daily TCS use
No Low
Gu 2013 (19) Cochrane English RMIT University
Nottingham University, UK.
NIHR
One author was a principal
investigator on one included study





Gu 2014 (20) Non-Cochrane English Not stated None known Chinese herbal medicine
versus TCS
No Critically low







English HTA programme One author received payment from
Novartis for lectures on the
epidemiology of atopic eczema in
1999.
Another author has acted as












Non-Cochrane English Not stated One author had primary contact with
the 2nd case and has a blog on the
subject matter in this systematic
review
No RCTs found Yes (case reports on steroid
withdrawal)
Critically low
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
Labedz 2019
(25)
Non-Cochrane English Not stated None known TCS versus TCI No Critically low
Legendre
2015 (26)
Non-Cochrane English No funding One author is a consultant and
investigator for two pharmaceutical
companies. One author is a speaker
and/or on the advisory board for five
pharmaceutical companies.
Only searched for cohort or
case control studies
Yes (comparing TCS and TCI) Critically low





English NIHR One author reports grants and fees







Once a day versus twice a











English Not stated None known TCS versus TCI No Low
Schmitt 2011
(30)
Non-Cochrane English No funding One author has served as paid







Non-Cochrane English Not stated Some authors have served as
investigators, consultants, speakers,







Non-Cochrane English Financial support for writing by
Valent Pharmaceutical North America
LLC. They declared that “Valeant
Pharmaceuticals had no role in the
design of the literature searches, or
analysis and presentation of results.”
Authors have either participated in
paid contract research, received
travel expenses for presentations,
consulting fees, speakers, on advisory







Singh 2012 (33) Non-Cochrane English Not stated None known TCS versus TCS
TCI versus TCS
TCS versus placebo/vehicle
Yes (single arm TCS study) Critically low
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
Svensson
2011 (34)
Non-Cochrane English Funded by Astellas Pharma Europe
Ltd.
One author was a paid employee of
Astellas Pharma Europe Ltd and one
author undertook paid consultancy
work for Astellas Pharma Europe Ltd.
TCI versus TCS No Critically low







Cochrane English Oak Foundation, Denmark
NIHR




Non-Cochrane English No grants, honoraria or royalties
were received supporting the writing
of the paper.
One author was a consultant with
Perrigo, Inc. with regard to topical
corticosteroid treatment. All authors
have no financial or other potential
conflicts of interest.
Two RCTs included but
analysed as observational
data
Yes – single arm cohort studies Critically low
Yan 2008 (38) Non-Cochrane English Not stated Not stated TCI versus TCS No Critically low
Key: TCI=topical calcinueirin inhibitor; TCS=topical corticosteroids; RCT=Randomised Controlled Trial; NIHR= National Institute for Health Research
1. Ashcroft D, Dimmock P, Garside R, Stein K, Williams H. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic
dermatitis: Meta-analysis of randomised controlled trials. BMJ 2005;330(7490):516-22.
2. Ashcroft DM, Chen L-C, Garside R, Stein K, Williams HC. Topical pimecrolimus for eczema Cochrane Database Syst Rev [Internet]. 2007; (4). Available
from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005500.pub2/abstract.
3. Barnes L, Kaya G, Rollason V. Topical Corticosteroid-Induced Skin Atrophy: A Comprehensive Review. Drug Saf. 2015;38(5):493-509.
4. Braham S, Pugashetti R, Koo J, Maibach H. Occlusive therapy in atopic dermatitis: overview. J Dermatolog Treat. 2010;21(2):62-72.
5. Broeders J, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors
with topical corticosteroids for atopic dermatitis: A 15-year experience. J Am Acad Dermatol. 2016;75(2):410-9.e3.
6. Callen J, Chamlin S, Eichenfield L, Ellis C, Girardi M, Goldfarb M, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J
Dermatol. 2007;156(2):203-21.
7. Chen S, Yan J, Wang F. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: A meta-analysis of randomized
clinical trials. J Dermatolog Treat. 2010;21(3):144-56.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
8. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da SEM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev [Internet]. 2015;
(7). Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009864.pub2/abstract.
9. de Tiedra A, Mercadal J, Lozano R. Prednicarbate versus fluocortin for inflammatory dermatoses: A cost-effectiveness study. PharmacoEconomics.
1997;12(2 Pt 1):193-208.
10. Devillers A, Oranje A. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic
dermatitis: a critical review of the literature. Br J Dermatol. 2006;154(4):579-85.
11. Dong Y, Zeng W, Li W, Ma H, Zheng W. Efficacy and safety of topical tacrolimus for childhood atopic dermatitis; a meta-analysis. [Chinese]. J Clin
Dermatol. 2017;46(4):239-42.
12. Eichenfield L, Tom W, Berger T, Krol A, Paller A, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: Section 2.
Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32.
13. Feldman S. Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses.
Curr Ther Res Clin Exp. 2005;66(3):154-71.
14. Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic Review and Meta-analysis Comparing Topical Corticosteroids With
Vehicle/Moisturizer in Childhood Atopic Dermatitis. J Pediatr Nurs. 2019;47:36-43.
15. Frangos J, Kimball A. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opin
Pharmacother. 2008;9(11):2001-7.
16. Froeschl B, Arts D, Leopold C. Corticosteroid therapy in the treatment of pediatric patients with atopic dermatitis (Structured abstract). Health
Technol Assess [Internet]. 2007; (4). Available from: http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32008100208/frame.html.
17. Gonzalez-Lopez G, Ceballos-Rodriguez R, Gonzalez-Lopez J, Feito Rodriguez M, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients
with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(3):688-95.
18. Green C, Colquitt J, Kirby J, Davidson P, Payne E. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical
corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2004;8(47):iii,iv, 1-120.
19. Gu S, Yang A, Li C, Lu C, Xue C. Topical application of Chinese herbal medicine for atopic eczema: A systematic review with a meta-analysis.
Dermatology. 2014;228(4):294-302.
20. Gu S, Yang AW, Xue CC, Li CG, Pang C, Zhang W, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev [Internet]. 2013; (9).
Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008642.pub2/abstract.
21. Hajar T, Leshem Y, Hanifin J, Nedorost S, Lio P, Paller A, et al. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in
patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-9.e2.
22. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1-191.
23. Iskedjian M, Piwko C, Shear N, Langley R, Einarson T. Topical calcineurin inhibitors in the treatment of atopic dermatitis: A meta-analysis of current
evidence. Am J Clin Dermatol. 2004;5(4):267-79.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
24. Juhász ML, Curley RA, Rasmussen A, Malakouti M, Silverberg N, Jacob SE. Systematic Review of the Topical Steroid Addiction and Topical Steroid
Withdrawal Phenomenon in Children Diagnosed With Atopic Dermatitis and Treated With Topical Corticosteroids. J Dermatol Nurses Assoc. 2017;9(5):233-
40.
25. Łabędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized 
clinical trials. Postepy Dermatol Alergol. 2019;36(6):752-9.
26. Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of
topical treatment: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992-1002.
27. Li R, Zhu H, Fan L, Ni S, Feng C, Wu Z. Efficacy and tolerability of topical tacrolimus in the treatment of atopic dermatitis: A systematic review of
randomized controlled trials. [Chinese]. J Clin Dermatol. 2007;36(12):757-60.
28. Nankervis H, Thomas K, Delamere F, Barbarot S, Rogers N, Williams H. Scoping systematic review of treatments for eczema2016 2016/05/None.
29. Penaloza Hidalgo B, Knight T, Burls A. A systematic review of effectiveness and cost effectiveness of tacrolimus ointment for topical treatment of
atopic dermatitis in adults and children Health Technol Assess [Internet]. 2004; (4):[81 p.].
30. Schmitt J, Von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin
inhibitors for atopic eczema: Systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415-28.
31. Sidbury R, Tom W, Bergman J, Cooper K, Silverman R, Berger T, et al. Guidelines of care for the management of atopic dermatitis: Section 4.
Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(6):1218-33.
32. Siegfried E, Jaworski J, Kaiser J, Hebert A. Systematic review of published trials: Long-term safety of topical corticosteroids and topical calcineurin
inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16 (75).
33. Singh S, Mann B. Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: A systematic review. Clin
Cosmet Investig Dermatol. 2012;5:61-8.
34. Svensson A, Chambers C, Gånemo A, Mitchell S. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of
atopic dermatitis. Curr Med Res Opin. 2011;27(7):1395-406.
35. Tang T, Bieber T, Williams H. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically
useful? J Allergy Clin Immunol. 2014;133(6):1615-25.e1.
36. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen AP, Arents BW. Emollients and moisturisers for eczema. Cochrane Database Syst Rev
[Internet]. 2017; (2). Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012119.pub2/abstract.
37. Wood Heickman L, Davallow Ghajar L, Conaway M, Rogol A. Evaluation of Hypothalamic-Pituitary-Adrenal Axis Suppression following Cutaneous
Use of Topical Corticosteroids in Children: A Meta-Analysis. Horm Res Paediatr. 2018;89(6):389-96.
38. Yan J, Chen S, Wang X, Zhou W, Wang F. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol.
2008;25(1):117-20.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
Appendix 6 – Characteristics and safety data from the included studies









Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events
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followed up for
additional 2 weeks














Age: ≥ 12 years 
Sample size: 229
participants
Local application site skin
reactions
No clinically significant






Clobetasol lotion = 4/96 patients
(4.2%); Clobetasol cream = 1/100
patients (1%)
Vehicle = 6/33 patients (18.2%)







Duration not specified in
review
Risk of bias not assessed














Incidence of adverse events or
treatment related adverse
events
Clobetasol foam = 8%







Risk of bias not assessed






























Severity: ≥30% BSA 
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it was measured)
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Risk of bias not assessed








Open label Phase II safety
study
2 weeks treatment
Risk of bias not assessed














7/30 (23.3%) had adrenal
insufficiency (ACTH stimulation
testing, measuring serum cortisol
levels).
 47% of children (aged 6-11)
 0% of adolescents (aged 12-
17)
 27% of adults ( ≥18 years)  











Risk of bias not assessed












Skin thinning 1 case of skin
thinning reported (not clear if in a
psoriasis or eczema patient – but
assume its eczema as this is the








(Cochrane risk of bias
tool: low risk of selection,
attrition and other
biases. Unclear risk of
reporting and
performance bias, High
risk of detection bias. (12))
(Cochrane risk of bias
tool: unclear risk of
selection bias, high risk
from no blinding. (3))
Intervention: Fluticasone 0.05%
cream twice daily
(hydrocortisone 2.5% for the








months to 18 years




The participants did not report
any in either group.
No further details regarding
other possible treatment related
adverse events were reported.
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(up to 14 days treatment)
(Cochrane risk of bias
tool: low risk of selection
bias from sequence
generation, unclear risk
of selection bias from
allocation concealment,
low risk from blinding. (3))
Intervention: Hydrocortisone
17-butyrate cream (0.1%)
maximum application of 2g (four
fingertip units) per day (n=49)
Comparator: Cipamfylline cream
(1.5 mg of cipamfylline per gram
of cream) used up to a
maximum of 2 g (four fingertip








No difference in cutaneous
adverse events which were
possibly or probably related to
treatment in either group (p =
0.13)
The adverse events were mostly
application site reactions,
including itching, stinging or
burning, and drug reactions.
Unspecified adverse events
Hydrocortisone group: 20/49
(40.8%) participants reported 41
adverse events in total.
Emollient: 29/52 (55.8%)
participants reported 63 adverse
events in total.








Risk of bias not assessed
Intervention: Fluticasone
propionate four times daily
(n=221)




Age: children from 3




Withdrawal due to adverse
events
Topical corticosteroids: 4
participants in total from this
study and from Hebert 2007
The number of participants














(Cochrane risk of bias
tool: low risk of selection
bias from sequence
generation. Unclear risk
of selection bias from
allocation concealment,
unclear risk from blinding
and other biases: Two
out of 60 participants
were excluded from the




furoate 0.1% cream, twice a day
(n=20)
Comparator: placebo of distilled
water in 1% dimethyl sulfoxide
mixed with the identical cream
base as used for the 15(R/S)-
methyl-lipoxin A4 (n=20)
Comparator: 15(R/S)-methyl-
lipoxin A4 0.1% cream (n=20)
Severity: all
severities
Age: children from 1
month to 1 year old
Sample size: 60
participants
None of the safety tests (e.g. full




with baseline for all three
treatment groups.
No clinical adverse events were
reported.
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(Duration not specified in
the review)












One report by a participant using
























The review authors only reported

























The review authors only reported









(21 to 29 days treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Hydrocortisone











HPA axis suppression (no data
for vehicle group)
5/63 (7.9%) children in the
hydrocortisone group (measured
using ACTH stimulation testing,
measuring serum cortisol levels)
After TCS discontinuation,
children with biochemical adrenal
insufficiency had complete
resolution at retesting.
The number of participants

















The number of participants
reporting at least 1 adverse
event
Hydrocortisone: 48/139 (34.5%)
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(Fishbein 2019
(16))
Risk of bias not assessed
in any of the included
systematic reviews.
Comparator: Vehicle, twice daily
(n=145)
Age: children 3















(3 to 4 weeks)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Fluticasone










2/43 (4.7%) children (measured
using ACTH stimulation testing,
measuring serum cortisol levels)
After TCS discontinuation,











Risk of bias not assessed














0/20 (0%) children (measured
using ACTH stimulation testing,







(3 to 4 weeks treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Fluticasone











0/42 (0%) children (measured
using ACTH stimulation testing,
measuring serum cortisol levels)







(Cochrane risk of bias
tool: low risk of selection,
attrition, reporting and
other biases. Unclear risk
of performance bias.
Intervention: Hydrocortisone
butyric propionate 0.1% twice
daily (n=40)
Comparator: Stelatopia (2%
sunflower oil, fatty acids,




months to 4 years (
mean age 2.3 years)
Sample size: 80
participants
No participants reported adverse
events
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High risk of detection
bias. (12))
(Cochrane risk of bias
tool: unclear risk of














































Clinically significant in one








Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Halcinonide
0.025% cream, twice daily, on
one arm
Comparator: Placebo cream
unspecified, twice daily on the




months to 15 years
(mean age 8 years)
Sample size: 86
children
The number of participants








RCT (but safety data only
presented for one arm)
(21 days treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Prednicarbate
cream 0.25% (2 applications per
day) (n=34)
Comparator:mometasone
cream 0.1% twice daily (no
safety data given)
Severity: Disease
duration = mean 4.1
years ± 2.7
Age: children 2-12







Rampini 1992 (34) RCT (but safety data only
presented for one arm)
Intervention: Prednicarbate
cream/unguent 0.25% (2
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dropouts, no ITT analysis,
(19))
Comparator:methylprednisolone
aceponate 0.1% once daily (no
safety data given)
Age: children 0.3 to








RCT (but safety data only










cream 0.25% (2 applications per
day) (n=49)
Comparator: fluocortolone




years ± 8.2 (range
0.25 to 39 years).
Age: adults 19 to 65












RCT (but safety data only
presented for one arm)
(21 days treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Prednicarbate
cream 0.25% (2 applications per
day) (n=41)
Comparator: fluocinolone cream
0.025% twice daily (no safety
data given)
Severity: Disease
duration = mean 6.4
years ± 8.6 (range 0-
40).
Age: adults 18 to 77















Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Prednicarbate



























No adverse events reported
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Risk of bias not assessed









Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Alclometasone









All normal (measured via
morning cortisol)







(Cochrane risk of bias
tool: unclear risk of
selection, performance
and attrition bias. Low
risk of reporting and
other biases. High risk of
detection bias. (12))
(Cochrane risk of bias
tool: unclear risk of
selection bias from
sequence generation and
risk from blinding. Low




acetate 1% cream twice daily,
was applied one side of the
body for 4 weeks followed by





fatty acids) applied twice daily





months to 10 years
(mean age 5.8 years)
Sample size: 30
participants








Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Desonide 0.05%










One event reported in TCS group
but not thought to be related to
treatment
Withdrawal due to adverse
events
TCS group: 4 in total from this
study and from Eichenfield 2006
The number of participants
reporting at least 1 adverse
event
Desonide: 85/425 (20 %)
participants
Vehicle: 46/157 (29.3%)
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Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Hydrocortisone
1% ointment twice daily, applied
to one arm.
Comparator: 5% dexapanthenol
ointment twice daily, applied to
the other arm at the same time.
Severity:mild to
moderate
Age: children 2 years












(Cochrane risk of bias










acetate 1% cream twice daily on





fatty acids) twice daily on one















(Cochrane risk of bias
tool: Unclear risk of
selection and
performance bias. High
risk of detection bias.




acetate 1% cream twice daily on
one side of the body
Comparator:Moisturiser
containing spent grain, Vitellaria
paradoxa (formerly
Butyrospermum parkii) extract
plus Argania spinosa kernel oil









The investigators stated that “no







(Cochrane risk of bias
tool: unclear risk of
selection bias and risk
from blinding. (3))
Intervention: 1% hydrocortisone
solution once daily for 1st week
then twice daily up to 3 weeks
Comparator: 6% miltefosine
solution once daily for 1st week
then twice daily up to 3 weeks
Severity:moderate
to severe




Local topical adverse events





These adverse events included
pruritus, burning, tingling and dry
No systemic adverse events No withdrawals because of
adverse events
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(Cochrane risk of bias
tool: unclear risk of
selection bias and high




cream, containing 2% ethanolic










Three participants in the







Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Fluocinolone
acetonide 0.01% twice daily
(n=45)





Age: children from 2




Two participants out of 45







(3-10 years follow up)
Risk of bias not assessed















Plasma cortisol levels - no change









Risk of bias not assessed


























Risk of bias not assessed
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Risk of bias not assessed


































(up to 3 weeks
treatment)




(Cochrane risk of bias
tool: unclear risk of
selection bias and from
blinding. (3))
(Cochrane risk of bias
tool: unclear risk of





prednisolone 0.1% (n=129) once
daily in the evening to all
affected body surface areas for a
minimum of 2 weeks and a
maximum of 3 weeks and
cleared areas treated for an
additional 7 days post clearance.
Also applied a vehicle ointment
in the morning to maintain
blinding.
Comparator: Tacrolimus 0.03%
(n=136), applied twice daily,
morning and evening, to all
affected body surface areas for a
minimum of 2 weeks and a
maximum of 3 weeks and
cleared areas treated for an
additional 7 days post clearance.
Severity: severe to
very severe






























(3 weeks treatment twice
daily, plus 3 weeks follow
up with once daily
treatment)
Intervention: Fluticasone
0.005% ointment applied twice
daily to all affected areas except
eyelids until clearance, up to 3
weeks. All participants who
responded to treatment could
apply treatment once a day to
Severity:moderate
to severe
Age: children 2 to 15
years old
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(Jadad score 5/5 – risk
from allocation
concealment (53))
(Cochrane risk of bias
tool: unclear risk of
selection bias and from
blinding. (3))
(Cochrane risk of bias





Cochrane risk of bias tool:
low risk of selection,
performance, attrition,
reporting and other
biases. Unclear risk of
performance bias (56)).
the remaining lesions for
another 3 weeks (n=239)
Comparator: Tacrolimus 0.03%
ointment applied twice daily to
all affected areas except eyelids
until clearance, up to 3 weeks.
All participants who responded
to treatment could apply
treatment once a day to the





































(3 weeks of treatment –
then for a further 3
weeks either stop
treatment, once daily
treatment or switch to
other treatment twice
daily)
(Jadad score 5/5 – risk
from allocation
concealment (53))
(Cochrane risk of bias
tool: unclear risk of
selection bias and low
risk from blinding. (3))
Intervention: Fluticasone
0.005% ointment twice daily on
facial eczema lesions for 3
weeks or until clearance (n=279)
Comparator: Tacrolimus 0.1%
twice daily on facial eczema
lesions for 3 weeks or until
clearance (n=287)
For 21 days after the initial 3
weeks, the participants could
stop treatments if the facial
lesions had cleared; stay on the
same treatment once a day; or












































BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open





(up to 3 weeks
treatment)




(Cochrane risk of bias
tool: unclear risk of
selection bias and unclear
risk from blinding. (3))
(Jadad scale: 3/5 (59))
(Cochrane risk of bias
tool: unclear risk of
selection bias, adequate
blinding, inadequate loss
to follow up. (60))
Intervention: Betamethasone
valerate 0.1% applied twice
daily on all affected areas except
for the head and neck for up to
3 weeks or until complete
clearance if this was sooner
(n=42)
Comparator: Pimecrolimus 1%
applied twice daily on all
affected areas except for the
head and neck for up to 3 weeks
or until complete clearance if
this was sooner (n=45)
Severity:moderate






























(52 weeks. Twice daily
until clearance, restarted
with flares)




(Cochrane risk of bias
tool: unclear risk of
selection bias, low risk
from blinding. (3))
(Jadad scale: 3/5 (59))










(face) (Mild potency) twice daily
until complete clearance and




twice daily until complete
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(52 weeks, as prescribed
until 7 days after
clearance, then restarted
with flares)




(Cochrane risk of bias
tool: unclear risk of
selection bias, risk from
no blinding. (3))
Intervention: Hydrocortisone
butyrate 0.1% ointment (potent)
and Hydrocortisone acetate 1%
ointment (face) (Mild potency)
twice daily, as prescribed, for a
flare until 7 days after clearance,
as many times as required in 1
year (n=40)
Comparator: Tacrolimus 0.1%
ointment twice daily, as
prescribed, for a flare until 7
days after clearance, as many






















None in either group
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(Jadad score 4/5 – risk
from allocation
concealment (53))
(Cochrane risk of bias
tool: unclear risk of
selection bias, unclear
risk from blinding. (3))
(Jadad scale: 5/5, (59))
(Cochrane risk of bias









blinding and ITT analysis
done. (65))
Intervention: Hydrocortisone
butyrate 0.1% twice daily for 3
weeks (n=186)
Comparator: Tacrolimus 0.1%
twice daily for 3 weeks (n=191)
Comparator: Tacrolimus 0.03%
twice daily for 3 weeks (arm not
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(26 weeks) twice daily
treatment until 7 days
after clearance, then
whenever a flare occurs)
(Jadad score 5/5; (53))
(Cochrane risk of bias
tool: unclear risk of
selection bias,, low risk
from blinding. (3))
(Jadad scale: 5/5, (59))
(Cochrane risk of bias
tool: High risk of attrition




(Cochrane risk of bias
tool: unclear risk of
selection bias, unclear if





(face) (Mild potency) twice daily
until 7 days after clearance of
eczema each time a flare of
eczema occurred for 6 months
(n=485)
Comparator: Tacrolimus 0.1%
twice daily until 7 days after
clearance of eczema each time a
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(Cochrane risk of bias

























(Jadad scale: 5/5, (59))
Intervention: Betamethasone
valerate 0.12% twice daily for
three weeks (n=89)
Comparator: tacrolimus 0.1%

























(2 weeks treatment, 28
weeks follow up)





ointment 1% (mild potency)
twice daily for head/neck and
hydrocortisone butyrate
ointment 0.1% (potent) for
trunk and limbs for 2 weeks
then hydrocortisone 1% (mild
potency) twice daily for flares.
(n=124)
Comparator: Tacrolimus 0.03%
twice daily for 3 weeks then
tacrolimus once daily and




Age: children 2 to
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of observer or patients,
(53))
(Cochrane risk of bias
tool: Unclear risk of
selection and detection




(Cochrane risk of bias
tool: low risk of selection
bias, from blinding of
participants and missing
data. Unclear risk from
Intervention: Clobetasone
0.05% twice daily (n=15)
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pivalate 0.1% twice daily (n=19)
Intervention: Clocortolone 0.1%















More frequent in those treated
with Tacrolimus 0.1%.
Pruritus
Commonly reported in both
arms.
(No numerical data provided in
the review)







(260 weeks used until
clearance or according to
country’s label.
Medication reinstated
when a flare occurred))
(Jadad score 3/5 – risk
from allocation
concealment, no blinding
of observer or patients,
(53))
Intervention: A moderate
potency or mild potency TCS
used according to the country’s






Age: children age 3
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Zero cases in either group
Growth rate and immune system
No difference between groups








(Jadad score 5/5 – risk
from allocation
concealment (53))
(Cochrane risk of bias
tool: unclear risk of
selection bias, unclear
risk of blinding (3))
(Jadad scale: 5/5, (59))
(Cochrane risk of bias





Cochrane risk of bias tool:
low risk of selection,
performance, attrition,
reporting and other bias.
Unclear risk from blinding
outcome assessors (56)).
(Cochrane risk of bias
tool: adequate method of
randomisation and
allocation concealment,
blinding done, ITT used.
(65))
Intervention: Hydrocortisone
acetate 1% twice daily (n=185)
Comparator: Tacrolimus 0.1%
ointment twice daily (n=186)
Comparator: Tacrolimus 0.03%
ointment twice daily (arm not
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(Cochrane risk of bias
tool: unclear risk of
selection bias. Unclear
risk from blinding. (3))
(Jadad scale: 4/5, (59))
(Cochrane risk of bias
tool: Unclear risk of
selection bias (allocation






Cochrane risk of bias tool:
low risk of selection,
performance, attrition,
reporting and other bias.
Unclear risk from blinding
outcome assessors (56)).
Intervention: Hydrocortisone


























































unclear if blinded ,ITT
analysis used (65))
Intervention: Topical
corticosteroids on one side of
the body, twice daily
Comparator: Tacrolimus 0.1%
on one side of the body, twice
daily
Severity: severe
























Age: not specified in
the review
Lymphoma
No increased risk of lymphoma
with TCI or TCS when compared
against controls.
Super potent TCS: OR 1.2, 95% CI
0.8 to 1.8
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Risk of bias not assessed
in any of the included
systematic reviews.
Comparator: controls (not




Low potency TCS: OR 1.1, 95%CI
0.7 to 1.6
Pimecrolimus: OR 0.8, 95%CI 0.4
to 1.6









Risk of bias not assessed















Increased risk with topical
corticosteroids (related to
potency) but no numerical data







(followed up between the
years of 2002 to 2006)
Risk of bias not assessed
in any of the included
systematic reviews.



















increased risk in TCI and TCS
patients when compared with the
general population, but with






Open label, single group
(6 to 12 months of
treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: No steroids









One participant had skin thinning
when using TCS prior to
treatment with tacrolimus – but
this ameliorated after 6 months
of treatment with tacrolimus.









Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events
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prednicarbate cream, twice daily
(moderate potency)








Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Trimaconiolone
acetonide 0.1%, twice daily
(potent)
Comparator: Alclomethasone









There was suppression after 2
weeks, but no further after 3 (no
further details).






(15 days treatment, 30
days follow up)
(Cochrane risk of bias
tool: unclear risk of
selection bias and unclear
risk from blinding. (3))
Intervention:Micronized
desonide cream 0.1% (mild
potency) 1 to 5 days twice daily
(in hospital), days 6 and 7 once




(potent) 1 to 5 days twice daily
(in hospital), days 6 and 7 once
daily, then alternate days until
day 15 (n=14)
Severity: severe











(Up to 42 days
treatment)
(Cochrane risk of bias
tool: unclear risk of
selection bias and unclear
risk from blinding. (3))
Intervention:Mometasone
furoate 0.1% once daily after a
bath (N=13) (potent)
Comparator: Desonide cream




















Risk of bias not assessed
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(16 weeks: twice daily for
2-4 weeks until stabilised
then ‘as required’ for 12
weeks)
(Cochrane risk of bias
tool: unclear risk of
selection bias, unclear
risk from blinding. (3))
Intervention: Fluticasone
propionate 0.005% ointment
(potent), twice daily for 2-4
weeks until stabilised then ‘as
required’ for 12 weeks (n=70)
Comparator: Hydrocortisone 1%
cream (mild potency), twice
daily for 2-4 weeks until










1 participant but not clear which
group






(Difference between groups: p =
0.32 a)





(Difference between groups: p =
0.52 a)






(Difference between groups: p =
0.93 a)






(Difference between groups: p =
0.45 a)
Kirkup 2003a and b:






(Difference between groups: p =
0.97 a)












withdrawals, no ITT, (19))
Intervention: Alclometasone
dipropionate 0.05% twice daily
(moderate potency)
Comparator: Hydrocortisone 1%














(Duration 0.7 to 18.7
years)
Risk of bias not assessed













corticosteroids: no change in
plasma cortisol levels
Potent topical corticosteroids:
suppression in 4/4 (100%)
patients
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(Duration not specified in
the review)
Risk of bias not assessed













Review authors reported “Also
concerns for negative effects on
linear growth, although reports





(Duration not specified in
the review)
Risk of bias not assessed












Review authors reported “Also
concerns for negative effects on
linear growth, although reports





(Duration not specified in
the review)
Risk of bias not assessed













Review authors reported “Also
concerns for negative effects on
linear growth, although reports
have given mixed conclusions”









Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events











(16 weeks: twice daily for
2-4 weeks until stabilised
then intermittently for 12
weeks)
(Cochrane risk of bias
tool: unclear risk of
selection bias, unclear
risk from blinding. (3))
Intervention: Fluticasone
propionate 0.005% ointment,
twice daily for 2-4 weeks until
stabilised then intermittently for
12 weeks (n=66)
Comparator: Hydrocortisone
butyrate 0.1% cream (potent),
twice daily for 2-4 weeks until
Severity:moderate

















(Difference between groups: p =
0.93 a)
Kirkup 2003a and b: Respiratory
tract infection
Kirkup 2003a and b:






(Difference between groups: p =
0.97 a)
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stabilised then intermittently for
12 weeks (n=62)
(Difference between groups: p =
0.32 a)











(Difference between groups: p =
0.45 a)






Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Prednicarbate
ointment 0.25%, twice daily
(moderate potency) (n=36)
Comparator: Flucortin ointment
0.75%, twice daily (assumed
moderate potency) (n=31)
Severity: Disease
duration – mean 7.7









Flucortin: 2/31 patients (6.5%)
(Difference between groups: p =
0.16 a)












open label, five dropouts,
no ITT (19))
Intervention: Desonide 0.05%
ointment, twice per day (mild
potency)
Comparator: Hydrocortisone











Normal in both groups (measured
using ACTH stimulation testing,

















twice daily (n=16) (mild potency)
Comparator: 1% hydrocortisone









No cases - measured by a
magnifying lamp
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E









Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events






followed up for 12 weeks
after)
(Cochrane risk of bias
tool: low risk of selection
bias (random sequence
generation), and other
biases. Unclear risk of
selection (allocation
concealment), detection
and attrition bias. High
risk of performance and
reporting bias. (100, 101)
Intervention: Clobetasol
propionate ointment, 3 times
daily (n=97)
Comparator: Chushi Zhiyang
















The five events were








(Cochrane risk of bias
tool: unclear risk of
selection, detection,
attrition, reporting and
other bias. High risk of
performance bias (100, 101))
Intervention:Mometasone
furoate cream, once daily (n=50)
Comparator: Huanglian Qingdai
















Minor adverse events such as
burning, dryness and scaling of






(Cochrane risk of bias
tool: unclear risk of
selection, detection,
attrition, and reporting
bias. High risk of
Intervention: Hydrocortisone
butyrate cream, twice daily
(n=47)
Comparator: Jingfang mixture








Minor adverse events such as
burning, dryness and scaling of
the skin were reported in the TCS
groups.
(No numerical data provided in
the review)
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performance bias. Low





(Cochrane risk of bias
tool: unclear risk of
selection, detection,
attrition, and reporting




acetonide acetate cream, twice
daily (n=51)
Comparator: Kouqiang Xiaoyan





days to 2 years
Sample size: 104
participants
No adverse events in either
group









Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events









(Cochrane risk of bias
tool: unclear risk of
selection bias, high risk
from no blinding. (3))
Intervention: fluocinonide
cream 0.1% applied once daily
(n=63)
Comparator: fluocinonide cream





12 to <18 years
(cohort 1); 6 to <12
years (cohort 2); 2 to
<6 years (cohort 3);





Once daily: 0/63 (0%)
















(4 weeks treatment) )









propionate 0.05% cream once
daily (plus vehicle once daily for
blinding) (n=137)
Comparator: Fluticasone








Number of events possibility,
probably or almost certainly
related to study medication
Once daily: 26 events
Twice daily: 24 events
(most were skin disorders)
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Number of adverse events
possibly related to medication
Once daily: 6 events
Twice daily: 8 events
Number of adverse events
probably related to medication
Once daily: 9 events
Twice daily: 3 events
Number of adverse events
almost certain related to
medication
Once daily: 6 events
Twice daily: 3 events
(Mainly included skin related
disorders including exacerbation







(4 weeks treatment) )
















butyrate) once daily and











Folliculitis in all skin areas after 1
week of treatment – treatment
stopped
Once daily: 1/75 participants
(1.3%)
Twice daily: 0/75 participants
(0%)
(Difference between groups: p =
0.50 a)
Folliculitis - treatment continued
Once daily: 0/75 participants
(0%)
Twice daily: 4/75 participants
(5.3%)
(Difference between groups: p =
0.14 a)
Burning, itching and stinging
sensations – treatment
continued
Once daily: 3/75 participants
(4%)
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Twice daily: 0/75 participants
(0%)












blinding, and no ITT used.
(107))
Intervention: Fluticasone
propionate cream 0.05% once
daily and vehicle once daily
(n=77)
Comparator: Fluticasone









Once daily: 2/77 participants
(3%)
Twice daily: 0/77 participants
(0%)
(Difference between groups: p =
0.30 a)
Dryness
Once daily: 2/77 participants
(3%)
Twice daily: 0/77 participants
(0%)
(Difference between groups: p =
0.30 a)
Pruritus
Once daily: 0/77 participants
(0%)
Twice daily: 1/77 participants
(1%)
(Difference between groups: p =
0.50 a)
Erythema





Once daily: 0/77 participants
(0%)
Twice daily: 1/77 participants
(1%)
(Difference between groups: p =
0.50 a)
Irritation
Once daily: 0/77 participants
(0%)
Twice daily: 1/77 participants
(1%)
None of adverse events were
serious or unexpected
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( (3 weeks treatment)













no ITT analysis, (19))
Intervention:Mometasone
furoate in fatty cream base
(Elocon) once daily (n=49)
Comparator: Hydrocortisone 17-
butyrate in fatty cream base
(Locoid) twice daily (n=45)
Severity: severity
score at least 4.5/9




Treatment related side effects
Were only a few and similar in
both groups. They included
stinging, burning, itching,



































partial blinding, and ITT
used. (107))
Intervention: Fluticasone






















Once daily cream: 0/95
participants (0%)
Twice daily cream: 1/91
participants (1%)
(Difference between groups: p =
0.48 a)
Once daily ointment: 1/100
participants (1%)
Twice daily ointment: 0/90
participants (0%)
(Difference between groups: p =
0.54 a)
Striae
Once daily cream: 0/95
participants (0%)
Twice daily cream: 0/91
participants (0%)
(Difference between groups: n/a)
Once daily ointment: 1/100
participants (1%)
Twice daily ointment: 0/90
participants (0%)
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(Difference between groups: p =
0.54 a)
For the three events listed above:
two of these patients had a
previous history of skin changes,
and therefore only one report
was newly observed (group not






(3 weeks treatment) )


























Telangiectasia of mild severity in
last 2 weeks
Once daily: 4/30 participants
(13.3%)
Twice daily: 5/30 participants
(16.7%)
(Difference between groups: p =
0.72 a)
Possible skin thinning (“Loss of
skin marks and reduced
elasticity”)
Once daily: 0/30 participants
(0%)
Twice daily: 1/30 participants
(3.3%)
(Difference between groups: p =
0.50 a)
Local application site reactions
Did not occur
Systemic reactions
None – all patients checked for
blood test and value varied
within a very narrow range.

















butyrate 0.05% lotion once daily
at 9pm (n=9)
Comparator: Clobetasone 17-
butyrate 0.05% lotion twice
daily at 8am and 3pm (n=13)
Comparator: Clobetasone 17-
butyrate 0.05% lotion twice








No significant difference in serum
cortisol and ACTH levels before
and after TCS administration in
any of the three groups, or any
differences between groups
Adverse effects not reported
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Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events
























(Cochrane risk of bias
tool: low risk of selection
(sequence generation),
attrition and other






propionate 0.005% ointment on
two consecutive days per week,
once daily (n=68)
Intervention: Fluticasone
propionate 0.05% cream on two
consecutive days per week, once
daily (n=70)












No new visual signs observed in









(Cochrane risk of bias
tool: low risk of selection
(sequence generation),
and attrition bias.



















No evidence in either group
Adverse events related to
treatment (cutaneous)
Fluticasone: 2 events (flexural
hyperpigmentation, folliculitis,
transient telangiectasia) (n=39)





No evidence in either group




No cases in either group
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(Cochrane risk of bias
tool: low risk of attrition
bias. Unclear risk of
selection, bias from
blinding and reporting




propionate 0.05% cream (once
daily 4 days per week for 4
weeks, then once daily 2 days











Adverse events related to
treatment















*One participant received 345
days of treatment and had a
cortisol stimulation level after
treatment of 17 ug/dL (normal
was >=18 ug/dL). The other
participant was treated for 280
days and had a cortisol










(Cochrane risk of bias
tool: low risk of attrition,
and other biases. Unclear









no ITT, only data up to
first relapse analysed, (19))
Intervention: Fluticasone
propionate 0.005% ointment (2















No change in geometric mean










(Cochrane risk of bias
tool: high risk of selection
bias (sequence
generation). Low risk of
attrition bias and bias
from blinding. Unclear
Intervention: Prednisolone
aceponate 0.1% cream (two













Adverse events related to
treatment
Zero in both groups
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Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events







Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: Dry occlusion with
clobetasol propionate lotion




















(Cochrane risk of bias
tool: low risk of selection
(sequence generation),
attrition, reporting and





Intervention: wet wrap therapy
with diluted mometasone
furoate 0.1% ointment (n=19)





months to 10 years




Mometasone under wet wrap:
9/19 (47%)
Emollient under wet wrap: 2/20
(10%)
(Difference between groups: p =
0.03 a)
Severe folliculitis
Mometasone under wet wrap:
1/19 (5.2%)
Emollient under wet wrap: 0/20
(0%)
(Difference between groups: p =
0.47*)
Secondary infected eczema
Mometasone under wet wrap:
0/19 (0%)
Emollient under wet wrap: 2/20
(10%)
(Difference between groups: p=
0.30 a)
Beginning of decubitus
Mometasone under wet wrap:
0/19 (%)
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Emollient under wet wrap: 2/20
(10%)
(Difference between groups: p =
0.30a)
Decubitus
Mometasone under wet wrap:
2/19 (11%)
Emollient under wet wrap: 1/20
(5%)








(Cochrane risk of bias
tool: unclear risk of
selection bias, unclear
risk from blinding. (3))
Intervention: wet wrap therapy
with mometasone furoate 0.1%,
twice daily





Age: children aged 2












(Up to 14 days
treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: wet wrap therapy
with diluted beclomethasone









Short term growth and bone
turnover
No significant differences found
between outcomes before and
during a median treatment












Prospective, side to side
(observational)
(1 week treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: wet wrap therapy
with 10-50% dilution fluticasone
propionate 0.05% cream (daily)
Comparator: emollient (only 2
participants) or no comparator
Severity: severe
Age: children 5














“Nearly all” had decreased
cortisol, 3 children were HPA
suppressed (from Braham 2010
review).
Two patients having a 9am serum
cortisol < 0.2 umol/L (0.09 and
0.03) after treatment for 7 days.
Those participants used 957
ug/m2and 1125 ug/m2 of steroid
cream. There was no follow up
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Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: wet wrap therapy
with 10% dilution mometasone




















(2 to 5 days treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: wet wrap therapy
with 25% dilution
betamethasone or
hydrocortisone 1%, twice daily





Age: children aged 9





Some during follow up at home
HPA axis suppression
Transient low morning cortisol.







(up to 5 days treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: wet wrap therapy
with 10% dilution
betamethasone 0.1% cream or
hydrocortisone 0.5%





Age: children aged 4









Retrospective side to side
(observational)
(1 week treatment)
Risk of bias not assessed
in any of the included
systematic reviews.
Intervention: wet wrap therapy
with diluted fluticasone
propionate 0.05% (daily re-wet
















One case of striae in a patient
taking inhaled steroids.
HPA axis suppression
Transient low morning cortisol,
12.5% with HPA suppression




(48 to 72 hours
treatment)




Zero adverse events in either
group. Did not observe severe
cutaneous events.
Did not observe systemic events
such as growth retardation or
HPA suppression – but these
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(Gonzalez-Lopez
2017 (132))
(Cochrane risk of bias
tool: unclear risk of
selection and
performance bias. High
risk of performance bias.
Unclear risk of attrition,
reporting and other
biases. (132))
(Cochrane risk of bias
tool: unclear risk of
selection bias, high risk








events were not actively
investigated.






(Cochrane risk of bias
tool: low risk of selection,
reporting and other
biases. High risk of
performance and
attrition bias. Unclear
risk of detection bias.
Gonzalez-Lopez 2017)
(Cochrane risk of bias







Intervention: wet wrap therapy
with hydrocortisone 1% twice
daily then overnight the second
week(n=10)
Comparator: Hydrocortisone 1%
twice daily then daily (n=9)
Severity:moderate





Wet wrap therapy with
hydrocortisone: 2/10 participants






Did not observe severe cutaneous
events.
Did not observe systemic such as
growth retardation or HPA
suppression – but these events






(4 weeks – not clear if
treatment given for
whole 4 weeks)
(Cochrane risk of bias






Intervention: wet wrap therapy
with hydrocortisone 1% for 24
hours – could be reduced to 12












Wet wrap therapy with
hydrocortisone: 5/28 participants




(Difference between groups: p =
0.14 a)
Did not observe systemic events
such as growth retardation or
HPA suppression – but these
events were not actively
investigated.
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detection and other
biases. High risk of
performance and
attrition bias. (132))
(Cochrane risk of bias
tool: unclear risk of
selection bias, low risk
from blinding. (3))
Did not observe severe cutaneous
events.
Footnotes:
*This column refers to the systematic review in which the safety data was extract from. The trial may have also been included in other systematic reviews, but no additional safety data was reported.
Abbreviations: RCT = randomised controlled trial; TCS = topical corticosteroids; TCI = topical calcineurin inhibitors; HPA = hypothalamic pituitary adrenal, WWT = wet wrap therapy; RR = risk ratio; OR: odds
ratios; 95% CI = 95% confidence interval; CHM = Chinese herbal medicine; IPA = Investigator's Global Assessment; BSA = Body Surface Area
aP value calculated by review authors using RevMan software.
b The P value calculated from Fisher’s Exact Test was significant: 0.0298 (but in the overview, this study is included in a meta-analysis)
cThe P value calculated from Fisher’s Exact Test was significant: 0.0298 (but in the overview, this study is included in a meta-analysis)
dTheP value calculated from Fisher’s Exact Test was significant: 0.0352 (but in the overview, this study is included in a meta-analysis)
e TheP value calculated from Fisher’s Exact Test was significant: 0.0289 (but in the overview, this study is included in a meta-analysis)
f TheP value calculated from Fisher’s Exact Test was significant: 0.0267 (but in the overview, this study is included in a meta-analysis)
Where studies include “diluted” topical corticosteroids and we aren’t sure how this affects the potency, we have put the topical corticosteroids in the potency classification based on the undiluted version.
The terms skin atrophy and skin thinning were both used in the included reviews – for consistently we have used skin thinning throughout.
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Appendix 7: edits made to meta-analyses and data from Broeders et al 2016 1
1) Switched the forest plot labels around so topical corticosteroids are the intervention and
topical calcineurin inhibitors are is the comparator.
2) Amended a data error given in the skin infection forest plot where the number of events and
participants were given the wrong way round for topical corticosteroids and topical
calcineurin inhibitors in Luger et al 2004 2.
3) Added skin atrophy data from Sigurgeirsson et al 2015 3 into the forest plot – this is not
provided in the publication but is given in online correspondence on the journal website
4) Changed to random effects instead of fixed effects as the decision was based on whether
the I2 value which is not appropriate.
5) Bieber et al 2007 4 was listed as “least potent” in table I of the publication – but according to
the Australian potency classification it should be classified as potent.
6) In table I, the topical calcineurin inhibitors given for Mandelin et al 2010 5 is tacrolimus 1% -
this should be 0.1%.
7) In table I, the therapy given for Hofman et al 2006 6 was hydrocortisone acetate 0.1%.
However, patients used hydrocortisone ointment 1% (mild potency) twice daily for
head/neck and hydrocortisone butyrate ointment 0.1% (potent) for trunk and limbs for 2
weeks then hydrocortisone 1% twice daily for flares.
References
1. Broeders J, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized
clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic
dermatitis: A 15-year experience. J Am Acad Dermatol. 2016;75(2):410-9.e3.
2. Luger T, Van Leent E, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an
emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144(4):788-94.
3. Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar M, Zhu X, et al. Safety and
efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015;135(4):597-
606.
4. Bieber T, Vick K, Folster-Holst R, Belloni-Fortina A, Stadtler G, WormM, et al. Efficacy and
safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children
and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184-9.
5. Mandelin J, Remitz A, Virtanen H, Reitamo S. One-year treatment with 0.1% tacrolimus
ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A
randomized, double-blind, comparative trial. Acta Derm Venereol. 2010;90(2):170-4.
6. Hofman T, Cranswick N, Kuna P, Boznanski A, Latos T, Gold M, et al. Tacrolimus ointment
does not affect the immediate response to vaccination, the generation of immune memory, or
humoral and cell-mediated immunity in children. Arch Dis Child. 2006;91(11):905-10.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E








BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
References:
1. Luger T, Lahfa M, Folster-Holst R, Gulliver W, Allen R, Molloy S, et al. Long-term safety and tolerability
of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic
dermatitis. J Dermatolog Treat. 2004;15(3):169-78
2. Mandelin J, Remitz A, Virtanen H, Reitamo S. One-year treatment with 0.1% tacrolimus ointment
versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: A randomized,
double-blind, comparative trial. Acta Derm Venereol. 2010;90(2):170-4
3. Reitamo S, Ortonne J, Sand C, Cambazard F, Bieber T, Folster-Holst R, et al. A multicentre,
randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in
adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152(6):1282-9
4. Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar M, Zhu X, et al. Safety and efficacy of
pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015;135(4):597-606
5. Doss N, Reitamo S, Dubertret L, Fekete G, Kamoun M, Lahfa M, et al. Superiority of tacrolimus 0.1%
ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of
the face: results from a randomized, double-blind trial. Br J Dermatol. 2009;161(2):427-34
6. Doss N, Kamoun M, Dubertret L, Cambazard F, Remitz A, Lahfa M, et al. Efficacy of tacrolimus 0.03%
ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence
from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy
Immunol. 2010;21(2 Pt 1):321-9.
7. Hofman T, Cranswick N, Kuna P, Boznanski A, Latos T, Gold M, et al. Tacrolimus ointment does not
affect the immediate response to vaccination, the generation of immune memory, or humoral and
cell-mediated immunity in children. Arch Dis Child. 2006;91(11):905-10
8. Luger T, Van Leent E, Graeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an
emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144(4):788-94
9. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann P, et al. Efficacy and safety of
tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with
atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547-55
10. Reitamo S, Van Leent E, Ho V, Harper J, Ruzicka T, Kalimo K, et al. Efficacy and safety of tacrolimus
ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J
Allergy Clin Immunol. 2002;109(3):539-46
11. Reitamo S, Harper J, Bos J, Cambazard F, Bruijnzeel-Koomen C, Valk P, et al. 0.03% Tacrolimus
ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children
with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J
Dermatol. 2004;150(3):554-62
12. Sikder M, Al Mamun S, Khan R, Chowdhury A, Khan H, Hoque M. Topical 0.03% tacrolimus ointment,
0.05% clobetasone butyrate cream alone and their combination in older children with atopic
dermatitis - An open randomized comparative study. J Pak Assoc Dermatol. 2005;15(4):304-12
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-046476:e046476. 11 2021;BMJ Open, et al. Axon E
1
Appendix 9: subgroup analyses of TCS versus TCI – cutaneous adverse events
By different topical corticosteroid potencies
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By age of participants (children or adults)
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By individual topical calcineurin inhibitor (TCI)
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